Discovering new treatments for liver cancer using protein analysis
Proteogenomics-driven therapeutic discovery in hepatocellular carcinoma
This study is looking at liver cancer to find out how it works and discover new ways to treat it, especially for patients with hepatitis B, so that better treatment options can be developed for everyone affected by this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10817788 on NIH RePORTER |
What this research studies
This research focuses on hepatocellular carcinoma (HCC), a severe form of liver cancer with limited treatment options. By combining genomic data with advanced protein analysis techniques, the study aims to uncover the molecular mechanisms that drive HCC, leading to the identification of new biomarkers and potential drug targets. The collaboration between teams in the US and China will leverage their combined expertise to enhance therapeutic discoveries specifically for HCC related to hepatitis B virus. Patients may benefit from new treatment strategies developed through this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hepatitis B virus-related hepatocellular carcinoma.
Not a fit: Patients with other types of liver cancer not related to hepatitis B virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments and diagnostic tools for liver cancer patients.
How similar studies have performed: Previous research in proteogenomics has shown promise in identifying new cancer biomarkers and therapeutic targets, indicating a strong potential for success in this approach.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Zhang, Bing — Baylor College of Medicine
- Study coordinator: Zhang, Bing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.